LAUSANNE, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 11:30 a.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website at ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days. Ab ...

Agree Realty is a large net-lease REIT, with an attractive yield and plenty of opportunity for growth ahead of it.Agree Realty (ADC -0.62%) has a lofty dividend yield of 5%, which is drastically higher than the 1.3% on offer from the S&P 500 and notably above the 4.3% from the average real estate investment trust (REIT), using Vanguard Real Estate Index ETF (VNQ -0.97%) as a proxy.But is this high-yield REIT the right dividend stock for you? Here's what you need to know.Agree Realty had a tough year in 2011 ...

-BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstrated a highly differentiated preclinical monotherapy efficacy profile, the potential for broader therapeutic margin than other Trop-2 ADCs currently in development, and synergistic affects when combined with anti-PD1 therapy-Biohaven also entered into a clinical supply agreement with Regeneron to study the combination of BHV-1510 with Regeneron's anti-PD-1 Libtayo® (cemiplimab-rwlc) in th ...

Image Source This article was co-produced with Wolf Report. It all comes down to what you want from your investments. Some of you want 300-500% RoR from an investment in a short time. If that's what you want here, I suggest that you stop reading. Today I'm sticking with safe stocks. The generation of safe, reliable, continuous income above the market level, while protecting my capital and my downside. We're looking for no less than 4-5% yield on average, with a 10-13% capital appreciation potential or there ...

- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to Historical Data for the ADC Alone - - Exploratory Analysis of a More Comparable Patient Population Showed an Approximately Six-Month Improvement in Median OS Among Patients Receiving Trilaciclib in Combination with the ADC Compared to Historical ADC Data - - Prolonged OS Observed in Patients Receiving Trilaci ...

YvanDube On our previous coverage of Agree Realty Corporation (NYSE:ADC) we compared it to WP Carey (WPC). WPC was the one that ultimately made it higher on our priority list. Those income investors are going to come back to this, probably in the early 2030s. WPC is likely to be in the penalty box, and valuation expansion won't be happening anytime soon. That said, objectively, if we can get past the misstep, WPC does have a splendid portfolio and one that could really do well if we enter a secular inf ...

porcorex It certainly doesn't hurt to own high-flying stocks like Dell Technologies Inc. (DELL) and NVIDIA Corporation (NVDA) these days, as the capital appreciation on these stocks over the past year has been equivalent to multiple years of market-level performance. Holding those stocks, however, can represent a dilemma for some investors, as it'd be unrealistic for any stock, no matter how great the business, to sustain the types of rallies they've recently had over the long run. This means that investors ...

文章核心观点 - 公司MediLink Therapeutics与BioNTech SE达成新的战略合作,BioNTech获得MediLink的TMALIN®抗体偶联药物(ADC)平台的独家许可权,用于开发几个新的靶点 [1][2][3] - 根据协议,MediLink将获得2500万美元的预付款,并有机会获得最高达18亿美元的里程碑付款以及未来全球销售的分成 [2] - 这次合作是双方现有合作的扩展,巩固了MediLink和BioNTech之间的战略伙伴关系,为双方在ADC领域的研发合作奠定了新的基础 [3][4] 公司概况 - MediLink Therapeutics是一家临床阶段的生物技术公司,专注于开发具有全球竞争力的联合药物 [5] - 公司开发了自主知识产权的TMALIN®ADC技术平台,可生成同质性高、药物抗体比高的ADC,用于治疗实体瘤 [6] - 公司总部位于中国苏州,在上海和美国波士顿设有研发基地 [5] TMALIN®技术平台 - TMALIN®是一种创新的ADC平台技术,采用双重切割机制,在肿瘤微环境和溶酶体内发挥作用 [6] - TMALIN®具有高亲水性、同质性好、血浆稳定性佳、肿瘤靶向性强等特点,在临床前研究中展现出良好的治疗窗口 [6] - 基于TMALIN®平台的多个ADC产品已进入临床试验阶段 [6]

J. Michael Jones/iStock Editorial via Getty Images I've been buying more of Agree Realty's (NYSE:ADC) common and preferred shares since the start of the year in response to the continued weakness of these securities. The commons are down 9% over the last 1 year with the 4.25% Series A preferreds (NYSE:ADC.PR.A) trading at a material 32% discount to their $25 per share liquidation value. The commons last declared a monthly cash dividend of $0.250 per share, kept unchanged from the prior month and $3 per ...

Realty Income is a great company, but it is a tortoise. You might want to consider Agree Realty and W.P. Carey instead.It would probably be a mistake to simply forget about net-lease giant Realty Income (O -0.25%). It is a well-run company, but it poses some problems for investors when you dig into the story a bit. For those looking for a bit more growth, competitors Agree Realty (ADC 0.53%) and W.P. Carey (WPC -0.96%) might be more attractive.I happily own Realty IncomeThere's nothing inherently wrong with ...